Skip to Content

CAPItello-280 trial aims to confirm findings from ProCAID trial.

At the recent ACSO-GU symposium, the design and study endpoints from the CAPItello-280 trial were presented. The trial-in-progress aims to confirm the findings made in the ProCAID study, investigating the effects and safety of adding capivasertib to docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer (CRPC).

Simon Crabb

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top